Navigation Links
Lilly Reports Fourth-Quarter and Full-Year 2008 Results
Date:1/29/2009

quisition on January 1, 2008. Therefore, 2009 earnings per share guidance of $4.00 to $4.25 will be compared to 2008 pro-forma non-GAAP earnings per share of $3.82.


    2009 Earnings Per Share Expectations:
                                                2009          2008
                                            Expectations    Results   % Growth
                                            ------------    -------   --------

     Earnings (Loss) per share
      (reported)                            $4.00 to $4.25  ($1.89)      NM
     Financial impact of ImClone
      acquisition, including in-process
      research and development and other
      charges                                     -           4.46
     Charges related to Zyprexa
      investigations                              -           1.20
     Asset impairments and restructuring
      charges (included in asset
      impairments, restructuring and other
      special charges)                            -            .30
     Asset impairments (included in cost
      of sales)                                   -            .04
     In-process research and development
      charges associated with SGX acquisition
      and in-licensing transactions with
      BioMS and TransPharma                       -            .10
     Benefit from resolution of IRS audit         -           (.19)
     Pro forma as if the ImClone acquisition
      was completed on January 1, 2008                        (.20)
                                            --------------  -------
     Earnings per share (pro forma
      non-GAAP)                             $4.00 to $4.25   $3.82   5% to 11%

     Additional information:
     Remove dilutive impact of ImClone
      acquisition                             .30 - .35        .20
                                            --------------  -------
     Earnings per share (pro forma
      non-GAAP) (excluding impact of

'/>"/>
SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division
3. Lauren Marangell, M.D. to Join Lilly; Internationally Recognized Expert in Depression Joins as Distinguished Lilly Scholar
4. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
5. Lillys CEO Calls for Reform of Nations Drug Safety System
6. Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
7. Lilly Grant to VA Will Enhance Services for Returning Combat Veterans
8. Lilly Delivers Strong Third-Quarter Results
9. Lilly and MacroGenics Announce Licensing and Collaboration Agreement
10. Eli Lilly and Company Aids California Recovery Effort
11. Eli Lilly and Company Announces 2007 Lilly Reintegration Awards Recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... Tampa, Florida (PRWEB) June 03, 2015 ... mobile friendly website yesterday, to make shopping for health ... The improved website has a fresh look and makes ... for medical centers around you. , Now, when ... prices for radiology and surgical procedures) they can see ...
(Date:6/3/2015)... 03, 2015 The Canton Group, a ... with technology, announced today that Tim Dodge has joined ... joins The Canton Group as it implements ... customer engagements. , Tim is a tech industry veteran ... variety of technology companies. Before joining The Canton Group, ...
(Date:6/3/2015)... 03, 2015 Follow us on ... has revolutionized disease treatment on account of their better ... diseases, such as rheumatoid arthritis. The industry is expected ... traditional small molecule drugs to biopharmaceuticals over the coming ... cell and gene therapies, and recombinant proteins has attracted ...
(Date:6/3/2015)... BC (PRWEB) June 03, 2015 Vancouver ... announced that the firm will now handle personal injury ... Greater Vancouver on the rise, more and more people ... year bus accidents cause needless suffering, serious injury and ... a result of a bus accident in BC you ...
(Date:6/3/2015)... Seattle, WA (PRWEB) June 03, 2015 ... health insurance exchange technology, has announced that CEO Jonathan ... (AHIP) Institute 2015 on June 4, 2015. The ... and digital technologies are disrupting traditional business models in ... new business value. , WHAT: Digital Transformation and ...
Breaking Medicine News(10 mins):Health News:Save On Medical Launches New Mobile-Optimized Website 2Health News:The Canton Group Appoints Tim Dodge as Chief Marketing Officer 2Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 4Health News:Jiwa Law Corporation Now Handles Personal Injury Claims Involving Bus Accidents 2Health News:Array Health’s CEO to Present at America’s Health Insurance Plans Institute 2015 2
... pair of new vaccines that not only fight cocaine and ... ,The study was conducted by a team of researchers ... Baylor College of Medicine (BCM). ,As part of ... subjects administered to it. ,Researchers found that study ...
... has shown a decline, thanks to the comprehensive program in ... the 2006 report shows a decline in the smoking ... the past year, smoking decreased among men (from 22.5% to ... declines followed a year-long ad campaign aimed at prompting more ...
... and even dabbled with French, but it was only when ... was established. ,Georgia has an IQ of ... Mensa. ,The youngest daughter of a chief executive and ... on intelligent children as the brightest two-year-old she has ever ...
... GmbH presented the first clinical evidence for the ... for patients suffering from chronic pain at ... Rheumatism (EULAR), 13-16 June 2007, Barcelona, Spain. Tapentadol, ... its kind, combining two analgesic principles, mu-receptor agonism ...
... university researchers has found a new modified drug for Alzheimers ... trials. ,Millions of people suffer from this ... Ghosh, the Purdue professor who led the creation of the ... be the first disease-modifying therapy. It may be able to ...
... Organization (WHO) based Special Programme for Research and ... new strategy for strengthening and expanding research ... ,The strategy builds on the programmes ... and enhancing research capacity in countries where parasitic ...
Cached Medicine News:Health News:New York Records Decline in Smoking Rate 2Health News:Two-year-old Joins Mensa, Becomes Its Youngest Ever Genius 2Health News:Phase II Data Show Efficacy and Tolerability of Tapentadol in Chronic Pain Treatment 2Health News:Phase II Data Show Efficacy and Tolerability of Tapentadol in Chronic Pain Treatment 3Health News:Modified Drug Therapy for Alzheimers Disease 2
(Date:6/3/2015)... 2015  OncoSec Medical Inc. ("OncoSec") (NASDAQ: ... immunotherapies, today announced that it has entered into ... purchase approximately $13.6 million of securities in a ... to such investors an aggregate of 2,469,091 shares ... $5.50 per share. The gross ...
(Date:6/3/2015)... Saudi Arabia , June 3, 2015  Varian Medical Systems ... software for the treatment of cancer, is expanding in the ... strategic operating entity in Saudi Arabia . ... with El Seif Development Group, was officially launched today at ... officer Dow Wilson. "This move represents the ...
(Date:6/3/2015)... , June 3, 2015  Lightlake Therapeutics ... addiction treatments based on its expertise in opioid ... Lightlake,s partner for treating opioid overdose with intranasal ... New Drug Application (NDA) to the United States ... spray formulation of naloxone, a drug intended to ...
Breaking Medicine Technology:OncoSec Medical Announces $13.6 Million Registered Direct Offering 2OncoSec Medical Announces $13.6 Million Registered Direct Offering 3Varian Establishes Local Entity in Saudi Arabia to Support Expansion in Middle East 2Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 2Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 3
... ANGELES, April 28, 2011 This afternoon, at ... Florida, ( http://www.epilepsy.com/etp/aedtrialxi ) Dr. Christopher DeGiorgio, principal ... of a Phase II randomized double-blind clinical trial ... study was conducted at UCLA and the University ...
... DIEGO, April 28, 2011 ResMed Inc. (NYSE: ... quarter ended March 31, 2011.  Revenue for the quarter ended ... a 12% increase on a constant currency basis) over the ... 31, 2011, income from operations was $64.0 million and net ...
Cached Medicine Technology:Positive Results Reported for Phase II Randomized Double-Blind Clinical Trial for the Treatment of Drug-Resistant Epilepsy Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™ 2Positive Results Reported for Phase II Randomized Double-Blind Clinical Trial for the Treatment of Drug-Resistant Epilepsy Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™ 3Positive Results Reported for Phase II Randomized Double-Blind Clinical Trial for the Treatment of Drug-Resistant Epilepsy Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™ 4ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011 2ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011 3ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011 4ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011 5ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011 6
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: